Date: 24 Aug 2012
Treatment of Advanced Parkinson’s Disease in the United States
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: As Parkinson’s disease (PD) progresses, patients and their families experience substantial health and economic burdens. Because motor fluctuations (also called ‘off-time’) are linked to poor quality of life and higher healthcare costs, minimizing off-time is an effective strategy for reducing costs associated with PD.
Objective: To assess the cost utility of rasagiline or entacapone as adjunctive therapies to levodopa versus levodopa/carbidopa/entacapone (LCE) versus standard levodopa monotherapy in patients with advanced PD and motor fluctuations in the US.
Methods: A 2-year stochastic Markov model was utilized to examine the cost effectiveness of treatments of advanced PD. The model assumed that patients transition health status every 4 months. Transition probabilities, including uncertainties, were estimated from clinical trial data. Medical costs, daily drug costs and utility weights were obtained from published literature.
Results: Over 2 years, all therapy options showed greater effectiveness than levodopa alone. Rasagiline + levodopa and LCE were cost saving from a payor perspective, while entacapone + levodopa was cost saving from a societal perspective. Mean benefits over 2 years were 0.12 (90% credibility interval [CI] 0.07, 0.18) additional quality-adjusted life-years (QALYs) for rasagiline + levodopa, entacapone + levodopa and LCE, 5.08 (90% CI 3.87, 6.28) additional months with ≤25% off-time for rasagiline + levodopa and 4.85 (90% CI 3.63, 6.06) additional months with ≤25% off-time for entacapone + levodopa and LCE versus levodopa alone.
Conclusion: From a payor perspective, rasagiline + levodopa and LCE were dominant therapies over levodopa monotherapy, while entacapone+ levodopa was effective at a higher cost. With no additional cost over a 2-year period, rasagiline + levodopa presents a valuable alternative to entacapone + levodopa, LCE and levodopa monotherapy in the treatment of advanced PD patients. Results from this cost-utility model and prior adjunctive clinical data provide ongoing support for the adjunctive use of rasagiline in advanced PD patients with motor fluctuations.
Oertel WH, Quinn NP. Parkinsonism. In: Brandt T, Caplan LR, Dichgans J, et al., editors. Neurological disorders: course and treatment. San Diego (CA): Academic Press, 1996: 715–72
Hudry J, Rinne JO, Keränen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinson’s disease in Finland. Annals Pharmacother 2006; 40: 651–7CrossRef
Vose D. Risk analysis, a quantitative guide. 3rd ed. Hoboken (NJ): John Wiley & Sons, 2008
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005; 365: 947–54PubMedCrossRef
Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”): I. Validation of the method. Am J Med 1982; 73: 833–8
Orsini L, Castelli-Haley J, Kennedy S, et al. Healthcare utilization and expenditures among privately insured patients with Parkinson’s disease in the US. Poster presented at the 8th Annual Meeting of the Movement Disorder Society’s International Congress; Jun 2004; Italy
US Department of Labor: Bureau of Labor Statistics. Consumer price index — all urban consumers (current series). 2006 [online]. Available from URL: http://data.bls.gov/PDQ/ outside.jsp?survey=cu [Accessed 2009 Apr 1]
Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson’s disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844–9PubMed
Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health-Syst Pharm 2000; 57: 953–62PubMed
Red Book for Windows. Version 61127, vol. 50. Montvale (NJ): Thomson PDR, 2009 Jan
World HealthOrganization Collaborating Centre for Drug Statistics Methodology [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2009 Jul 31]
- Treatment of Advanced Parkinson’s Disease in the United States
Clinical Drug Investigation
Volume 30, Issue 11 , pp 789-798
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors